Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 225

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Tagatose, a new antidiabetic and obesity control drug

Lu, Y., Levin, G. V., Donner, T. W. · 2008 · Diabetes, Obesity and Metabolism

Abstract

A potentially important new drug for treating type 2 diabetes, tagatose, is now in phase 3 clinical trial. The history, development, additional health benefits, mechanisms of action and the potential for the drug are presented in context with a review of the rapidly growing epidemic of type 2 diabetes and treatments for it. An epimer of fructose, the natural hexose tagatose was originally developed by Spherix Incorporated (formerly Biospherics Inc.) as a low‐calorie sugar substitute. Only 20% of orally ingested tagatose is fully metabolized, principally in the liver, following a metabolic pathway identical to that of fructose. Following a decade of studies, tagatose became generally recognized as safe for use in foods and beverages under US FDA regulation. The simple sugar is commercially produced by isomerization of galactose, which is prepared from lactose. Early human studies suggested tagatose as a potential antidiabetic drug through its beneficial effects on postprandial hyperglycaemia and hyperinsulinaemia. A subsequent 14‐month trial confirmed its potential for treating type 2 diabetes, and tagatose showed promise for inducing weight loss and raising high‐density lipoprotein cholesterol, both important to the control of diabetes and constituting benefits independent of the disease. Furthermore, tagatose was shown to be an antioxidant and a prebiotic, both properties cited in the maintenance and promotion of health. No current therapies for type 2 diabetes provide these multiple health benefits. The predominant side effects of tagatose are gastrointestinal disturbances associated with excessive consumption, generally accommodated within 1‐ to 2‐week period. The health and use potentials for tagatose (branded Naturlose ® for this use) are given with respect to current type 2 diabetes drugs and markets. Under an FDA‐affirmed protocol, Spherix is currently conducting a phase 3 trial to evaluate a placebo‐subtracted treatment effect based on a decrease in HbA 1c levels. Side effects, contraindications and possibly beneficial new findings will be carefully monitored. It is hoped that early results of the trial may become available by mid‐2008. If a subsequent NDA is successful, tagatose may fill a major health need.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2007.00799.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 225

Metadata

Authors
Lu, Y., Levin, G. V., & Donner, T. W.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2007-10-17
Volume
10
Issue
2
Pages
109-134
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1982678358
Cited by
225
References
7
FWCI
5.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tagatose, a new antidiabetic and obesity control drug. https://app.cochat.ai/papers/10.1111/j.1463-1326.2007.00799.x
The paper
Lu, Y., Levin, G. V., & Donner, T. W. (2008). Tagatose, a new antidiabetic and obesity control drug. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2007.00799.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.